CRISPR Therapeutics Financials - Benzinga

CRISPR Therapeutics AG

CRSPNASDAQ

Trade with Public

Trade with Public

$55.70

-0.06-0.11%

À la clôture: Sep 23, 5:00 PM EST

$56.20

0.440.79%

Pré-ouverture: 7:13 AM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Rapport sur les stocks

CRISPR Therapeutics Financials

CRISPR Therapeutics (CRSP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of $(2.40) per share

Benzinga Newsdesk

PRO
CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate

Benzinga Newsdesk

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.

Vandana Singh

CRISPR Therapeutics Earnings Report: Q4 Overview

Benzinga Insights

PRO
CRISPR Therapeutics Q4 EPS $(1.37) Misses $(1.09) Estimate, Sales $864.000K

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.09) by 25.92 percent. This is a 211.36 percent decrease over losses of $(0.44) per share

Benzinga Newsdesk

PRO
CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.24) by 5.26 percent. This is a 15.84 percent decrease over losses of $(1.01) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved